The default cash-pay GLP-1 economics look like this: patient comes in, gets a script, pays $400 to $600 a month for three or four months, and the clinic collects $1,600 to $2,400 in revenue with a margin that depends on the vendor and dose
Syringes are smaller, take up a lot less space, and have less waste
With expert support and transparent pricing, you can finally experience the long-term success you deserve.
Overall, the data suggest that the novel triple-acting hybrid peptides have significant potential as therapeutic options for obesity and diabetes
Most are weekly injections
Tirzepatides mechanism of action combines the effects of two incretin hormones: GIP and GLP-1